Presentation is current through November 21, 2014 and will be updated every Friday by 5pm. For the most up-to-date information, please visit www.cdc.gov/ebola.
*Presentation contains materials fro
...
m CDC, MSF, and WHO
more
Pwoteje Manje ak Dlo Apre yon Dezas oswa Sitiyasyon Ijans
The Public Health Burden of Commercial Tobacco Use
The burden of disease and death from commercial tobacco* use in the United States is
overwhelmingly caused by cigarettes
...
and other combustible tobacco products.
more
The Public Health Burden of Secondhand Exposure to Commercial Tobacco Smoke Secondhand smoke, the combination of smoke from burning commercial tobacco* products and the smoke breathed out by a person who is smoking, is deadly.
A summary of health effects, resources, and adaptation examples from health departments funded by CDC’s Climate and Health Program
AstraZeneca-SKBio in South Korea and Serum Institute of India
Preparedness planning is essential in order to respond effectively to outbreaks, including single case occurrences of highconsequence infectious diseases (HCID), such as the importation of a viral haemorrhagic fever (VHF) case
Monitoring implementation of the Dublin Declaration on Partnership to Fight HIV/AIDS in Europe and Central Asia: 2012 progress
Special Report
Euro Surveillance 2014;19(47):pii=20970, p.31-37
This report presents the main characteristics of Ebola emergency preparedness in three EU Member States. Findings are organised in five sections: preparedness planning, organisational structures, recourses and capacities, intersectoral
...
and cross-border collaboration, and country-specific findings
more
18 Janaury 2021
EU/EEA Member States and the UK have increased their laboratory capacity tremendously over the past 11 months as the majority of the Member States reported sufficient testing capacity until March 2021.
Many countries are ad
...
ding rapid antigen detection tests (RADT) to their testing strategies in order to reduce pressure on RT-PCR testing.
Some Member States have already included RADT in their case definition.
The main bottlenecks, such as shortages of laboratory consumables and human resources, as well as sample storing facilities, continue to exist and may affect the overall laboratory response to COVID-19.
more
The first update of the ECDC ventilation guidance document contains:
key new findings that emphasise four bundles of NPIs to reduce the risk of SARS-CoV-2 transmission in closed spaces;
updated references on the evidence of transmission in closed spaces;
recommendations based on the n
...
ew evidence and on national and international guidance; and
an overview of national guidance ventilation documents in the context of COVID-19 based on an inquiry sent to ECDC’s National Focal Points (NFPs) for Preparedness and Response and NFPs for Influenza and other respiratory diseases.
more
August 2020, The Africa Joint Continental Strategy for COVID-19 is underpinned by the need to limit transmission, prevent deaths and reduce associated harms. Participation by African nations in clin
...
ical trials is an essential step to ensure that sufficient data is generated on the safety and efficacy of the most promising vaccine candidates among the region’s populations.
While current COVID-19 clinical trial activity on the continent is limited, Africa has substantial experience and capabilities to conduct clinical trials for preventative vaccines across a range of diseases, and many organizations on the continent are working tirelessly to help prepare additional trials on potential COVID-19 vaccines. As the number of candidate vaccines in the development pipeline continues to increase, it will be important for organizations responsible for managing clinical trials in the region to partner with vaccine developers to identify potential and appropriate trial locations, provide support to remove any critical obstacles impeding commencement and progress of trials, and to provide oversight ensuring that trials are conducted safely and ethically.
more
African Union and the Africa Centers for Disease Control
...
and Prevention’s Africa Regulatory Taskforce has endorsed the Emergency Used Authorization for Janssen COVID-19 Vaccine
10 March 2021
more